Reference | <p style=/line-height:25px/>
<br>[1]. Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers By Cao, Ying Jun; From Antimicrobial Agents and Chemotherapy (2008), 52(5), 1630-1634.
<br>[2]. Skerlj R, Bridger G, McEachern E, Harwig C, Smith C, Kaller A, Veale D, Yee H, Skupinska K, Wauthy R, Wang L, Baird I, Zhu Y, Burrage K, Yang W, Sartori M, Huskens D, De Clercq E, Schols D.Design of novel CXCR4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.Bioorg Med Chem Lett. 2011 Mar 1;21(5):1414-8. Epub 2011 Jan 11.
<br>[3]. Skerlj R, Bridger G, McEachern E, Harwig C, Smith C, Wilson T, Veale D, Yee H, Crawford J, Skupinska K, Wauthy R, Yang W, Zhu Y, Bogucki D, Di Fluri M, Langille J, Huskens D, De Clercq E, Schols D.Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication.Bioorg Med Chem Lett. 2011 Jan 1;21(1):262-6. Epub 2010 Nov 6.
<br>[4]. Miller JF, Gudmundsson KS, Richardson LD, Jenkinson S, Spaltenstein A, Thomson M, Wheelan P.Synthesis and SAR of novel isoquinoline CXCR4 antagonists with potent anti-HIV activity.Bioorg Med Chem Lett. 2010 Apr 3.
<br>[5]. Skerlj RT, Bridger GJ, Kaller A, McEachern EJ, Crawford JB, Zhou Y, Atsma B, Langille J, Nan S, Veale D, Wilson T, Harwig C, Hatse S, Princen K, De Clercq E, Schols D.Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.J Med Chem. 2010 Apr 22;53(8):3376-88.
</p>
|